Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 19, Issue 15, 2001, Pages 3477-3482

  Phan, G Q ^a   Attia, P ^a   Steinberg, S M ^a   White, D E ^a   Rosenberg, S A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2; THYROTROPIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CORRELATION FUNCTION; DIARRHEA; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LUNG INSUFFICIENCY; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENTAL DISEASE; MYOCARDITIS; OLIGURIA; PRIORITY JOURNAL; SKIN METASTASIS; TACHYCARDIA; THYROID DISEASE; THYROID FUNCTION TEST; VITILIGO;

EID: 0035425425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.15.3477     Document Type: Article

References (29)

1. Malignant melanoma: Prevention, early detection, and treatment in the 21st century
2. Cancer statistics, 2001
3. Malignant melanoma: Cutaneous melanoma
4. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2
5. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
6. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
7. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer
8. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
9. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
10. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
11. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
12. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma
13. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma
14. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study
15. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy
16. Combination therapy with interferon alpha-2a and interleukin-2 for the treatment of metastatic melanoma
17. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma
18. In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2
19. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: A phase I study
20. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans
21. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
22. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
23. Thyroid dysfunction associated with immunotherapy for patients with cancer
24. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response
25. Thyroid dysfunction in 281 patients with metastatic melanoma or renal cell cancer treated with interleukin-2 alone
26. Vitiligo in patients with metastatic melanoma: A good prognostic sign
27. Prognostic significance of hypopigmentation in malignant melanoma
28. Vitiligo and cutaneous melanoma: A case study
29. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy